Today (12/8) Takeda announced the approval of the first modern preventative therapy for Hereditary Angioedema, TAHZYRO, for patients 12 and above from China’s National Medical Products Association (NMPA). The disease is chronic and life threatening, and it affects one in 50,000 people. In the phase three trial for TAKHZYRO, results showed that the drug reduced the mean number of monthly Hereditary Angioedema attacks by 87% relative to the placebo. The treatment is available in 20 countries worldwide.
Read more here.
More on: News Regulatory